Stockscreener 앱 받기
87.20
0.50%
-0.44
전일 마감가:
$87.64
열려 있는:
$88.25
하루 거래량:
1.19M
Relative Volume:
1.13
시가총액:
$4.39B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-29.10
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+6.91%
1개월 성능:
+9.85%
6개월 성능:
+86.01%
1년 성능:
+87.97%
1일 변동 폭
$86.24
$88.82
1주일 범위
$80.91
$88.82
52주 변동 폭
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
87.20 | 4.30B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
What analysts say about Soleno Therapeutics Inc. stockSuperior capital gains - Autocar Professional
What drives Soleno Therapeutics Inc. stock priceUnprecedented profit potential - Jammu Links News
Soleno gains as Betaville cites buyout interest (update) - MSN
Soleno Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentHigh-profit capital plays - Jammu Links News
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest
Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail
Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Public Stock Offering - TipRanks
In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria
Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini
Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive
Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada
Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com
Soleno Therapeutics prices public offering at $85 per share - Investing.com
Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa
Soleno Therapeutics prices $200M public offering - MSN
Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales By Investing.com - Investing.com South Africa
Soleno Therapeutics: Q2 2025 Results Signal Breakout Potential in Rare Disease Market - AInvest
Soleno Therapeutics announces preliminary financial and operational results for Q2 - MarketScreener
Soleno Therapeutics' $200M Secondary Offering: Catalyst for Growth or Dilution Danger Zone? - AInvest
Soleno Therapeutics Reports Q2 Preliminary Net Revenue - MarketScreener
Soleno Therapeutics Proposes $200 Million Public Offering - MarketScreener
Soleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XR - Nasdaq
Soleno Therapeutics Announces Preliminary Financial and - GlobeNewswire
Soleno's New Drug VYKAT XR Hits $33M Revenue in First Quarter Launch with Nearly 300 Prescribers - Stock Titan
Soleno Therapeutics (SLNO) Soars 5.93% on Regulatory Milestone - AInvest
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Soleno Therapeutics (SLNO) - The Globe and Mail
Soleno Therapeutics stock price target raised to $115 by Stifel on strong Vykat demand - Investing.com South Africa
Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential - Investing.com Nigeria
(SLNO) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics stock price target raised to $115 from $108 at Stifel - Investing.com Nigeria
Soleno Therapeutics stock price target raised to $115 from $108 at Stifel By Investing.com - Investing.com South Africa
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.34%
자본화:
|
볼륨(24시간):